California to Offer $11 Insulin Under New State Program

California Governor Gavin Newsom recently announced that starting January 2026, Californians will be able to buy insulin for just $11 per pen through the state’s new CalRx program.

The initiative is designed to make insulin more accessible and affordable for the many residents who depend on it to manage diabetes. For years, patients across the country have faced high insulin prices, often forcing them to ration doses or skip refills due to cost. By introducing its own low-cost version, California aims to ease that financial burden and ensure consistent access to this essential medication.

Through CalRx, the state partnered with Civica Rx to produce a long-acting insulin known as insulin glargine, which works the same as major brands but will be sold at a fraction of the usual price. Pharmacies will be able to offer a five-pack for about $55, making California one of the first states to directly manufacture and sell affordable insulin under a public program.

Governor Newsom said the effort reflects California’s commitment to addressing the high cost of prescription drugs and reducing reliance on pharmaceutical companies that have long dominated the market. He emphasized that this initiative is just the beginning, as the state plans to explore expanding CalRx to other essential medications in the future.

Health advocates praised the move as a major step forward for patients struggling with rising drug costs. If the rollout is successful, California’s approach could become a model for other states looking to take similar action.

For thousands of Californians living with diabetes, this program represents more than savings — it offers hope for affordable, reliable access to life-saving care.